Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients
Status:
Recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This is a phase II study assessing the activity and safety of metronomic chemotherapy with
cyclophosphamide and capecitabine and vinorelbine in advanced breast cancer patient in four
different cohort of patients:
1. Untreated (naïve) patients with endocrine responsive disease
2. Pretreated patients with endocrine responsive disease
3. Untreated (naïve) patients with triple negative disease
4. Pretreated patients with triple negative disease The primary endpoint will be the
progression-free survival